Company on Schedule to Commence Trial Late This Year VANCOUVER and MINNEAPOLIS, Sept. 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial. Following multiple discussions with FDA […]
Coronary/Structural Heart
CARMAT Receives Final Approval From the Patient Protection Committee for the Use of the Commercial Version of the Aeson® Heart in the EFICAS Study in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has received final approval from the Patient Protection […]
Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®
SUZHOU, China, Sept. 14, 2021 /PRNewswire/ — Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the third-generation transcatheter aortic valve (“TAVR”) system, following the first successful patient implant in Zhongshan Hospital of Fudan University. Led by Professor Ge Junbo, the procedure was completed successfully with support from the […]
Biotricity Unveils “Biokit” with 3 Personal Medical Devices to Expand into Cardiac Disease Management
Company Expects New Personal Medical Device Kit to be available to customer by early 2022 REDWOOD CITY, CA / ACCESSWIRE / September 14, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set […]
Medtronic Collaboration with Mpirik to Address Disparities in Care Associated with Sudden Cardiac Arrest
Aortic Stenosis Pilot Program with Mpirik Also Underway DUBLIN, Sept. 13, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac arrest (SCA), a condition in which the heart suddenly and unexpectedly […]
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Treatment with Omecamtiv Mecarbil in Black Patients Consistent with Overall Population and White Patients Cytokinetics to Host […]
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
Positive Findings in Journal of Alzheimer’s Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a First-in-Class Oral Epigenetic Therapeutic Candidate which Positively Regulates and Normalizes Genes that Cause Chronic Illness CALGARY, Alberta, Sept. 13, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. […]
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., Sept. 10, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, “Safe and Timely Antithrombotic Removal […]
ImpediMed Announces Presentation at Heart Failure Society of America Annual Scientific Meeting That Demonstrates Utility of SOZO® Digital Health Platform for Heart Failure Patients
Study Concludes that HF-Dex™ is a More Sensitive Method Than Weight in Monitoring Fluid Status in Heart Failure Patients CARLSBAD, Calif. and BRISBANE, Australia, Sept. 10, 2021 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to improve patient health, today announced a poster presentation […]
CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its CardiAMP® Cell Therapy Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306), which are being presented at the Heart […]



